Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe ...

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25Deepening responses observed over time in ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG). Patients with myasthenia gravis (MG) largely expressed negative ...

Medications for myasthenia gravis (MG) can include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and antibody fragment medications. While myasthenia gravis ...

The prevalence and incidence rates of myasthenia gravis in the elderly US population have increased from 2006 to 2019.

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Doctors may recommend oral medications such as pyridostigmine and various intravenous (IV) drugs for the treatment of myasthenia gravis. Thymectomy surgery and plasma exchange may also help.

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.